- Report
- August 2025
- 182 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- August 2025
- 192 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- October 2024
- 200 Pages
Global
From €3355EUR$3,750USD£2,869GBP
- Report
- March 2024
- 200 Pages
Global
From €3713EUR$4,150USD£3,175GBP
- Report
- March 2024
- 200 Pages
Global
From €3713EUR$4,150USD£3,175GBP
- Report
- August 2023
- 145 Pages
Global
From €2818EUR$3,150USD£2,410GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1790EUR$2,000USD£1,530GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2237EUR$2,500USD£1,913GBP
- Report
- April 2025
- 200 Pages
Global
From €7113EUR$7,950USD£6,083GBP
- Report
- December 2024
- 30 Pages
Global
From €2908EUR$3,250USD£2,487GBP
- Report
- September 2022
- 30 Pages
Global
From €2461EUR$2,750USD£2,104GBP
- Report
- May 2025
- 70 Pages
Japan
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
India
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Germany
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Italy
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Oman
From €4250EUR$4,750USD£3,635GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4250EUR$4,750USD£3,635GBP

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more